Skip to search formSkip to main contentSkip to account menu

cisplatin/paclitaxel

Known as: CDDP/TAX 
A combination of agents containing cisplatin and paclitaxel.
National Institutes of Health

Related topics

Related topics

3 relations
CisplatinPaclitaxelTaxol

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Chemotherapy for metastatic testicular cancer: The first nationwide multi‐institutional study by the Cancer Registration Committee of the Japanese Urological Association
To assess clinicopathological data and oncological outcomes focused on metastatic testicular cancer patients, who received… 
2010
2010
Feasibility, Toxicity, and Efficacy of Short Induction Chemotherapy of Docetaxel Plus Cisplatin or Carboplatin (TP) Followed by Concurrent Chemoradio ­ therapy for Organ Preservation in Advanced…
AbstractPurpose:Concurrent chemoradiotherapy (CRT) is standard treatment for advanced head and neck cancer. Whether short… 
2010
2010
CCL2 expression in primary ovarian carcinoma is correlated with chemotherapy response and survival outcomes.
CCL2, a chemokine, is expressed in normal human ovarian epithelium but down-regulated in ovarian adenocarcinomas. The association… 
2008
2008
Pharmacokinetics and safety of bevacizumab administered in combination with cisplatin and paclitaxel in cynomolgus monkeys
PurposeBevacizumab is the first anti-angiogenic monoclonal antibody approved for use in combination with chemotherapy for… 
Review
2005
Review
2005
Impact of induction concurrent chemoradiotherapy on pulmonary function and postoperative acute respiratory complications in esophageal cancer.
STUDY OBJECTIVE To evaluate the effects of induction concurrent chemoradiotherapy (cCRT) on pulmonary function and postoperative… 
2005
2005
Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study
BackgroundCisplatin, paclitaxel and 5-fluorouracil (5-FU) have demonstrated significant activity in patients with advanced… 
2003
2003
Phase II trial of single agent carboplatin followed by dose-intense paclitaxel, followed by maintenance paclitaxel therapy in stage IV ovarian, fallopian tube, and peritoneal cancers: a Southwest…
2001
2001
Topoisomerase IIα and other drug resistance markers in advanced non-small cell lung cancer
2000
2000
Raf-1 kinase activity predicts for paclitaxel resistance in TP53mut, but not TP53wt human ovarian cancer cells.
We have recently reported that there is a significant Raf-1 kinase dependency of paclitaxel resistance in human cervical tumor… 
1997
1997
Economic and policy implications of adopting paclitaxel as first-line therapy for advanced ovarian cancer: an Ontario perspective.
PURPOSE To determine the potential economic and policy implications that result from incorporating paclitaxel into first-line… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)